Distribution of high-risk HPV genotypes in women population in Serbia
Abstract
Background: Human papillomavirus (HPV) is the key etiological factor in cervical cancer development. The Cobas HPV test enables detection and partial genotyping of 14 high-risk (hrHPV) types, the test provides specific identification of HPV16 and HPV18, while simultaneously detecting the remaining high-risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). The introduction of HPV screening has major public health importance, particularly in prevention and early detection of premalignant lesions and cancer.
Methods: Within a national pilot project in Serbia, 9,510 women aged 30–65 were tested using RT PCR (Cobas 6800). Among samples positive for pooled hrHPV (794 samples) 405 were further analyzed by RT-PCR (Vector Best) to determine individual genotypes. Frequencies of hrHPV types were expressed as percentages.
Results: Overall hrHPV prevalence was 13%. The presence of hrHPV genotypes were either single or multiple, with two or more hrHPV types detected in some participants. HPV16 was detected in 245 (2.57%) of women, HPV18 in 69 (0.73%), while other hrHPV types were present in 794 (8.35%). In the subgroup (n = 405), HPV31 was most prevalent (26.17%), followed by HPV52 (17.53%), HPV51 (13.83%) and HPV66 (13.09%). Other types included HPV56 (11.85%), HPV33 (11.36%), HPV45 (11.11%), HPV58 (8.64%), HPV59 (7.65%), HPV68 (7.65%), HPV39 (6.67%) and HPV35 (5.68%).
Conclusions: Although non-16/18 HPV types are less frequently associated with cervical intraepithelial neoplasia and cancer, they still represent a significant cause of the disease. In the context of the Serbian population, these types account for 64% of all hrHPV-positive cases, with a notable prevalence of HPV31 (26.17%) and HPV52 (17.53%). Therefore, further stratification of high-risk non-16/18 HPV types is necessary to optimize screening algorithms and improve prevention and treatment strategies, including the broader implementation of the 9-valent vaccine.
Key messages: • Identification of dominant genotypes of hrHPV enables more targeted screening and potential reduction of cervical cancer incidence.
• These findings may support improved prevention strategies, vaccination optimization and strengthening of public health surveillance systems.
Related
- Prevalence, genotype distribution and associated factors of high-risk human papillomavirus among pregnant women in Eastern Ethiopia: a cross-sectional analysis nested within a population-based cohort study
- Prevalence of high-risk human papillomavirus genotypes and associated factors among HIV-infected women in a reproductive age group attending antiretroviral therapy in Nekemte town, Oromia, Ethiopia
- Motives to seek abortion among women of different income levels in Serbia
- Prevalence and genotype distribution of human papillomavirus (HPV) among adolescent girls and young women in a high HIV burden rural area of South Africa: a cross-sectional survey
- Human Papillomavirus Genotypes Among Women With Invasive Cervical Cancer in Nigeria: A Scoping Review
BibTeX
@article{grego2026distribution,
title = {{Distribution of high-risk HPV genotypes in women population in Serbia}},
author = {E Grego and V Jovanovic and J Ivanovic and M Cabrilo and N Civovic and M Ivanovic and M Sekulic and S Jovanovic},
journal = {The European Journal of Public Health},
year = {2026},
month = oct,
doi = {10.1093/eurpub/ckag169.1614},
url = {https://doi.org/10.1093/eurpub/ckag169.1614},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Distribution of high-risk HPV genotypes in women population in Serbia
AU - E Grego
AU - V Jovanovic
AU - J Ivanovic
AU - M Cabrilo
AU - N Civovic
AU - M Ivanovic
AU - M Sekulic
AU - S Jovanovic
PY - 2026
DA - 2026/10/01
JO - The European Journal of Public Health
DO - 10.1093/eurpub/ckag169.1614
UR - https://doi.org/10.1093/eurpub/ckag169.1614
AB - Background: Human papillomavirus (HPV) is the key etiological factor in cervical cancer development. The Cobas HPV test enables detection and partial genotyping of 14 high-risk (hrHPV) types, the test provides specific identification of HPV16 and HPV18, while simultaneously detecting the remaining high-risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). The introduction of HPV screening has major public health importance, particularly in prevention and early detection of premalignant lesions and cancer. Methods: Within a national pilot project in Serbia, 9,510 women aged 30–65 were tested using RT PCR (Cobas 6800). Among samples positive for pooled hrHPV (794 samples) 405 were further analyzed by RT-PCR (Vector Best) to determine individual genotypes. Frequencies of hrHPV types were expressed as percentages. Results: Overall hrHPV prevalence was 13%. The presence of hrHPV genotypes were either single or multiple, with two or more hrHPV types detected in some participants. HPV16 was detected in 245 (2.57%) of women, HPV18 in 69 (0.73%), while other hrHPV types were present in 794 (8.35%). In the subgroup (n = 405), HPV31 was most prevalent (26.17%), followed by HPV52 (17.53%), HPV51 (13.83%) and HPV66 (13.09%). Other types included HPV56 (11.85%), HPV33 (11.36%), HPV45 (11.11%), HPV58 (8.64%), HPV59 (7.65%), HPV68 (7.65%), HPV39 (6.67%) and HPV35 (5.68%). Conclusions: Although non-16/18 HPV types are less frequently associated with cervical intraepithelial neoplasia and cancer, they still represent a significant cause of the disease. In the context of the Serbian population, these types account for 64% of all hrHPV-positive cases, with a notable prevalence of HPV31 (26.17%) and HPV52 (17.53%). Therefore, further stratification of high-risk non-16/18 HPV types is necessary to optimize screening algorithms and improve prevention and treatment strategies, including the broader implementation of the 9-valent vaccine. Key messages: • Identification of dominant genotypes of hrHPV enables more targeted screening and potential reduction of cervical cancer incidence. • These findings may support improved prevention strategies, vaccination optimization and strengthening of public health surveillance systems.
SN - 1101-1262
SN - 1464-360X
ER -